Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RANI Rani Therapeutics Holdings

Post-Mkt 01-22 17:05:41 EST

1.39

+0.04

+2.96%

盘后1.38

-0.01-0.72%

17:04 EST

High1.44	Low1.34	Vol1.41M
Open1.35	D1 Closing1.35	Amplitude7.04%
Mkt Cap168.90M	Tradable Cap92.98M	Total Shares121.51M
T/O1.96M	T/O Rate2.10%	Tradable Shares66.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RANI","market":"US","secType":"STK","nameCN":"Rani Therapeutics Holdings","latestPrice":1.39,"timestamp":1769115600000,"preClose":1.35,"halted":0,"volume":1406920,"hourTrading":{"tag":"盘后","latestPrice":1.38,"preClose":1.39,"latestTime":"17:04 EST","volume":888,"amount":1235.129856,"timestamp":1769119473177,"change":-0.01,"changeRate":-0.007194,"amplitude":0.014388},"delay":0,"changeRate":0.02962962962962949,"floatShares":66891000,"shares":121511580,"eps":-0.758815,"marketStatus":"Post-Mkt","change":0.04,"latestTime":"01-22 17:05:41 EST","open":1.35,"high":1.435,"low":1.34,"amount":1957003.20928,"amplitude":0.07037,"askPrice":1.49,"askSize":2113,"bidPrice":1.38,"bidSize":373,"shortable":3,"etf":0,"ttmEps":-0.758815,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769130000000},"marketStatusCode":4,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":1.35,"preHourTrading":{"tag":"盘前","latestPrice":1.3336,"preClose":1.35,"latestTime":"09:23 EST","volume":34784,"amount":46379.3611872,"timestamp":1769091827768,"change":-0.0164,"changeRate":-0.012148,"amplitude":0.022222},"postHourTrading":{"tag":"盘后","latestPrice":1.38,"preClose":1.39,"latestTime":"17:04 EST","volume":888,"amount":1235.129856,"timestamp":1769119473177,"change":-0.01,"changeRate":-0.007194,"amplitude":0.014388},"volumeRatio":1.363181,"impliedVol":5.225,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/RANI","defaultTab":"news","newsList":[{"id":"2602306120","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cartesian Therapeutics (RNAC), Rani Therapeutics Holdings (RANI) and Haemonetics (HAE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602306120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602306120?lang=en_us&edition=fundamental","pubTime":"2026-01-10 03:51","pubTimestamp":1767988260,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cartesian-therapeutics-rnac-rani-therapeutics-holdings-rani-and-haemonetics-hae-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cartesian-therapeutics-rnac-rani-therapeutics-holdings-rani-and-haemonetics-hae-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0034390439.USD","BK4539","HCSG","LU0012050646.USD","IE00BLDYK493.USD","LU0205194284.USD","BK4007","RNAC","HAE","RANI","XLV","LU0029874061.USD","XBI","BK4581","LU1169590202.USD","IE00B64QTZ34.USD","LU1169589451.USD","BK4585","LABU","LU0128526141.USD","LU0106261612.USD","BK4139","BK4137","IE00B19Z6F94.USD","LU0205193047.USD","BK4588","BK4198"],"gpt_icon":0},{"id":"2602532042","title":"H.C. Wainwright Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602532042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602532042?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:36","pubTimestamp":1767958601,"startTime":"0","endTime":"0","summary":"In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings, with a price target of $11.0...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-rani-therapeutics-holdings-rani-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-rani-therapeutics-holdings-rani-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI"],"gpt_icon":0},{"id":"2601536629","title":"Rani Therapeutics Launches Phase 1 Trial of Oral GLP-1/GLP-2 Agonist for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2601536629","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601536629?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:01","pubTimestamp":1767873679,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. has announced the initiation of a Phase 1 clinical trial evaluating RT-114, an orally administered RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, for the treatment of obesity. The study will assess the safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of RT-114 compared to subcutaneous injection. Preclinical testing in animal models demonstrated that oral delivery of PG-102 via the RaniPill achieved bioavailability, pharmacokinetics, and weight loss effects comparable to subcutaneous injection. Results from this Phase 1 study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL5xPYzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4007","BK4588","BK4539","LU2210149790.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2095319765.USD","RANI","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","LU0314104364.USD","SG9999014039.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","NDAQ","BK4112"],"gpt_icon":0},{"id":"2601366512","title":"Rani Therapeutics Initiates Phase 1 Study of Rt-114 Ranipill® for the Treatment of Obesity in Collaboration With Progen","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366512","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366512?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA293J8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4539","RANI"],"gpt_icon":0},{"id":"2589681777","title":"Rani Therapeutics Amends Certificate of Incorporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2589681777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589681777?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:06","pubTimestamp":1764968783,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. has announced that its board of directors and stockholders have approved the adoption of an Amended and Restated Certificate of Incorporation. The revised certificate updates and restates the company's original incorporation documents, which were first filed in April 2021 and previously amended in July 2021. The changes were adopted in accordance with Delaware corporate law. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on De","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL92GM7y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","RANI"],"gpt_icon":0},{"id":"2586045604","title":"Rani Therapeutics Holdings Amends Certificate of Incorporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586045604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586045604?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:11","pubTimestamp":1764108707,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings, Inc. has announced that its board of directors and majority shareholders have approved certain corporate actions, including the adoption of an Amended and Restated Certificate of Incorporation. The company stated that these changes were duly adopted in accordance with its governing documents and Delaware law. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information containe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL1dDk1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"gpt_icon":0},{"id":"2581002969","title":"H.C. Wainwright Sticks to Its Buy Rating for Rani Therapeutics Holdings (RANI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581002969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581002969?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:56","pubTimestamp":1762516572,"startTime":"0","endTime":"0","summary":"In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings, with a price target of $11.0...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-rani-therapeutics-holdings-rani-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-rani-therapeutics-holdings-rani-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI"],"gpt_icon":0},{"id":"2581207450","title":"Rani Therapeutics Reports Financial Challenges Amid Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2581207450","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581207450?lang=en_us&edition=fundamental","pubTime":"2025-11-07 13:57","pubTimestamp":1762495036,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings, Inc. Class A ( ($RANI) ) has released its Q3 earnings. Here is a breakdown of the information Rani Therapeutics Holding...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rani-therapeutics-reports-financial-challenges-amid-innovation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rani-therapeutics-reports-financial-challenges-amid-innovation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI","BK4539","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2581455300","title":"Rani Therapeutics Holdings posts net loss of $31.9 million for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581455300","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581455300?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:43","pubTimestamp":1762465439,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. reported a net loss of $31.9 million for the nine months ended September 30, 2025, compared to a net loss of $40.9 million for the same period in 2024, representing a decrease of 22.0%. Net loss attributable to Rani Therapeutics Holdings Inc. was $19.4 million, down 8.1% from $21.1 million in the prior year period. Contract revenue was $0.2 million for the nine months ended September 30, 2025, attributed to evaluation services under an agreement with Chugai, while there was no contract revenue in the same period of 2024. The company continued to focus on developing its proprietary oral delivery technology for biologics and drugs and pursued partnerships with biopharmaceutical firms for the oral delivery of their products.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbqSGf5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4539","BK4007"],"gpt_icon":0},{"id":"2581804553","title":"Rani Therapeutics Appoints Abraham Bassan and Vasudev Bailey to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2581804553","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581804553?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:43","pubTimestamp":1762465385,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. has appointed Abraham Bassan and Vasudev Bailey, Ph.D. to its Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 06, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL3sXhT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"gpt_icon":0},{"id":"2581436550","title":"Rani Therapeutics Holdings Inc - Announces $1.085 Bln Collaboration With Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2581436550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581436550?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:30","pubTimestamp":1762464602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX4F92E7:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"gpt_icon":0},{"id":"2581043598","title":"Rani Therapeutics Holdings Inc - Expects Cash Runway to Extend Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2581043598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581043598?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:30","pubTimestamp":1762464602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX4F92E7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"gpt_icon":0},{"id":"2581043680","title":"Press Release: Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581043680","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581043680?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:30","pubTimestamp":1762464600,"startTime":"0","endTime":"0","summary":"-- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics --. -- Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus --. -- Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors --. SAN JOSE, Calif., Nov. 06, 2025  -- Rani Therapeutics Holdings, Inc.  , a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third quarter ended September 30, 2025 and provided a corporate update.October 2025, Rani Therapeutics entered into a Collaboration and License. Agreement with Chugai to develop an oral therapy combining the. includes an option for Chugai to expand its rights to up to five. Anomaly, Special Situations Funds, Invus, and Founder and Chairman, Mir. Imran, for the purchase and sale of shares of Rani Therapeu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4022","BK4232","LENZ","BK4539","R","RANI","BK4139"],"gpt_icon":0},{"id":"2580412370","title":"Stocks to Watch: Getty Images, Rani Therapeutics, Middlesex Water","url":"https://stock-news.laohu8.com/highlight/detail?id=2580412370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580412370?lang=en_us&edition=fundamental","pubTime":"2025-11-01 06:22","pubTimestamp":1761949320,"startTime":"0","endTime":"0","summary":"Getty Images shareholder Neuberger Berman Group, an investment firm, sold 63,000 shares. The stock declined 3% to $1.82 in after-hours trading Friday.Rani Therapeutics reported that the investment firm Samsara Biocapital bought a stake in the company. The stock gained 15% to $2.52 after the bell.Middlesex Water reported third-quarter revenue below expectations. Shares declined 2.4% to $56.10 after the close.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4231","BK4007","BK4172","BK4080","BK4077","BK4539","GETY","MSEX","BK4139","GTY","RANI"],"gpt_icon":0},{"id":"2579177473","title":"Rani Therapeutics Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Vasudev Jaiprakash Bailey","url":"https://stock-news.laohu8.com/highlight/detail?id=2579177473","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579177473?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:31","pubTimestamp":1761856264,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. has filed an initial statement of beneficial ownership. The filing lists Vasudev Jaiprakash Bailey as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL3ZjnBx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4539","BK4007"],"gpt_icon":0},{"id":"2578960436","title":"Director Makes Bold Move with Massive Stock Purchase in Rani Therapeutics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2578960436","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578960436?lang=en_us&edition=fundamental","pubTime":"2025-10-28 10:03","pubTimestamp":1761616987,"startTime":"0","endTime":"0","summary":"New insider activity at Rani Therapeutics Holdings ( ($RANI) ) has taken place on October 27, 2025. Director Mir A. Imran has made a significant in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-massive-stock-purchase-in-rani-therapeutics-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-massive-stock-purchase-in-rani-therapeutics-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI","BK4139","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2578046677","title":"Rani Therapeutics Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Abraham Bassan","url":"https://stock-news.laohu8.com/highlight/detail?id=2578046677","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578046677?lang=en_us&edition=fundamental","pubTime":"2025-10-28 07:27","pubTimestamp":1761607634,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. has filed an initial statement of beneficial ownership. The filing lists Abraham Bassan as a Director and the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nNDL3xYM3g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"gpt_icon":0},{"id":"2578621762","title":"Rani Therapeutics Launches Phase 1 Study for Obesity Treatment RT-114","url":"https://stock-news.laohu8.com/highlight/detail?id=2578621762","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578621762?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:33","pubTimestamp":1761586424,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings, Inc. Class A (($RANI)) announced an update on their ongoing clinical study. Rani Therapeutics Holdings, Inc. is conduct...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rani-therapeutics-launches-phase-1-study-for-obesity-treatment-rt-114?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rani-therapeutics-launches-phase-1-study-for-obesity-treatment-rt-114?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","RANI","BK4139"],"gpt_icon":0},{"id":"2578661783","title":"Rani Therapeutics Completes Private Placement of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2578661783","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578661783?lang=en_us&edition=fundamental","pubTime":"2025-10-27 18:31","pubTimestamp":1761561086,"startTime":"0","endTime":"0","summary":"An update from Rani Therapeutics Holdings ( ($RANI) ) is now available. On October 22, 2025, Rani Therapeutics Holdings announced the resignation o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rani-therapeutics-completes-private-placement-of-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rani-therapeutics-completes-private-placement-of-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","RANI","LENZ","BK4007"],"gpt_icon":0},{"id":"2578696915","title":"Rani Therapeutics (RANI): Evaluating Valuation Following Chugai Partnership and Major Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2578696915","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578696915?lang=en_us&edition=fundamental","pubTime":"2025-10-27 07:18","pubTimestamp":1761520718,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings (RANI) has attracted attention after announcing a major collaboration and license agreement with Chugai Pharmaceutical. This deal unlocks upfront payments, potential milestones, and expanded validation for its RaniPill technology.\nAt the same time, Rani completed a significant private placement led by top biotech investors. This move bolsters its balance sheet and supports continued innovation in oral biologics delivery.\nSee our latest analysis for Rani Therapeutics...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rani/rani-therapeutics-holdings/news/rani-therapeutics-rani-evaluating-valuation-following-chugai","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rani/rani-therapeutics-holdings/news/rani-therapeutics-rani-evaluating-valuation-following-chugai","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","RANI","BK4007"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.ranitherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.094},{"period":"3month","weight":-0.3541},{"period":"6month","weight":1.5376},{"period":"1year","weight":-0.0426},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.051033},{"month":2,"riseRate":0.75,"avgChangeRate":0.033575},{"month":3,"riseRate":0,"avgChangeRate":-0.179251},{"month":4,"riseRate":0.25,"avgChangeRate":0.187294},{"month":5,"riseRate":0,"avgChangeRate":-0.208482},{"month":6,"riseRate":0.25,"avgChangeRate":-0.118539},{"month":7,"riseRate":0.75,"avgChangeRate":-0.021139},{"month":8,"riseRate":0.4,"avgChangeRate":0.087585},{"month":9,"riseRate":0.2,"avgChangeRate":-0.146008},{"month":10,"riseRate":0.6,"avgChangeRate":0.658105},{"month":11,"riseRate":0.6,"avgChangeRate":0.053129},{"month":12,"riseRate":0.2,"avgChangeRate":-0.107417}],"exchange":"NASDAQ","name":"Rani Therapeutics Holdings","nameEN":"Rani Therapeutics Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rani Therapeutics Holdings(RANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rani Therapeutics Holdings,RANI,Rani Therapeutics Holdings股票,Rani Therapeutics Holdings股票老虎,Rani Therapeutics Holdings股票老虎国际,Rani Therapeutics Holdings行情,Rani Therapeutics Holdings股票行情,Rani Therapeutics Holdings股价,Rani Therapeutics Holdings股市,Rani Therapeutics Holdings股票价格,Rani Therapeutics Holdings股票交易,Rani Therapeutics Holdings股票购买,Rani Therapeutics Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rani Therapeutics Holdings(RANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}